WeedMD Inc. (TSXV:WMD) (“WeedMD” or the “Company”) is pleased to announce it has received an amendment to its license from Health Canada to include the sale of dried cannabis products from its facility in Aylmer, ON. In addition, the Company was licensed to sell starting materials to patients wishing to grow their own medicine under ACMPR, a practice WeedMD strongly supports. Full product offerings will appear on the WeedMD website when available.
“Obtaining our license to sell dried cannabis products is another major milestone for WeedMD. The expedited nature of the sales amendment came ahead of schedule and accelerates our timeline to revenue generation, and is a direct result of the dedication and quality efforts of our entire team,” said Bruce Dawson-Scully, CEO of WeedMD. “We look forward to opening our doors to patients and are excited to serve both patients in the long-term care and senior market as well the broader medical patient community.”
The license capacity has been amended and the fully retrofitted 26,000 sq. ft. indoor facility is now licensed to produce and sell 1,200kg of dried medical cannabis. In anticipation of the approval to sell, the Company has produced an inventory of approximately 300kg of dried cannabis product. The facility is currently capable of producing up to 1,300kg of dried cannabis per annum, with intentions to build out an oil extract lab as well further mothering and nursery rooms that could augment current production by up to 40%.
For more information, access our investor presentation on our website here. Also, please see the Company’s press release yesterday regarding its recent go-public transaction (WeedMD to Trade on the TSX Venture Exchange).
About WeedMD Rx Inc.
WeedMD Rx Inc. is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000 square foot, scalable production facility in Aylmer, Ontario with four acres of property for future expansion. WeedMD is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada through its comprehensive platform developed exclusively for that industry. WeedMD is dedicated to educating healthcare practitioners and furthering public understanding of the role medical cannabis can play as a viable alternative to prescription medication in relieving a variety of chronic medical conditions and illnesses.
To learn more, visit us at www.weedmd.com.
Follow WeedMD On:
This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Company’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Chief Financial Officer
WeedMD Rx Inc.
519-765-2440 Ext. 222
Click here to connect with WeedMD Inc. (TSXV:WMD) to receive an Investor Presentation.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact firstname.lastname@example.org, or